# SLU-PP-332 + BAM15

> The SLU-PP-332 + BAM15 blend is a supplier-defined research formulation that combines SLU-PP-332, a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, β and γ), with BAM15, a small-molecule mitochondrial uncoupler. Both raised energy expenditure in obese mice through different mechanisms. Neither is a peptide, the combination has not been studied, and neither is FDA approved.

Canonical: https://peptideproperties.com/compounds/slu-pp-332-bam15/

## Identity

- **Class:** Mitochondrial & Metabolic Research Compounds

## Key facts

- Components: SLU-PP-332 (ERRα/β/γ agonist) and BAM15 (mitochondrial uncoupler); neither is a peptide
- Listed by one supplier as 300 mcg capsules; the split between components is not stated
- SLU-PP-332: C18H14N2O2, 290.3 g/mol (PubChem)
- BAM15: an oxadiazolopyrazine diamine with two 2-fluorophenyl groups
- Both studied as energy-expenditure agents in obese mice, by different mechanisms
- No published study of the two compounds together
- Regulatory status: neither is FDA approved; evidence is preclinical

## What Is the SLU-PP-332 + BAM15 Blend?

The SLU-PP-332 + BAM15 blend is a research formulation that pairs two synthetic small molecules in a capsule product. It is listed by a single supplier as 300 mcg capsules, and the listing does not state how that amount is divided between the two compounds.Neither component is a peptide. SLU-PP-332 is an aryl acyl hydrazone, and BAM15 is N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine.[1] The blend is a supplier-defined combination. It is not an approved or standardized product, and its composition is set by the supplier.

## Components at a Glance

The blend pairs a nuclear receptor agonist with a compound that acts directly on mitochondrial membranes. SLU-PP-332 data are from PubChem; BAM15 has no PubChem record in the source data for this page.ComponentClassPrimary target or mechanism studiedMolecular weightSLU-PP-332Synthetic small-molecule pan-ERR agonistEstrogen-related receptors ERRα, ERRβ and ERRγ (highest potency at ERRα)290.3 g/molBAM15Synthetic small-molecule mitochondrial uncoupler (protonophore)Mitochondrial inner-membrane proton gradientNot listed

## Why These Compounds Are Studied Together

SLU-PP-332 and BAM15 are grouped because both increased energy expenditure and fat oxidation in obese mice, one by switching on mitochondrial gene programs and the other by uncoupling respiration from ATP synthesis. Published research on the specific combination is limited: no study has tested them together.
### SLU-PP-332: an ERR-driven exercise mimetic
SLU-PP-332 targets all three ERRs with the highest potency at ERRα. In mice it increased type IIa oxidative muscle fibers and exercise endurance through an ERRα-dependent acute aerobic exercise gene program.[2] In diet-induced obese and ob/ob mice, it increased energy expenditure and fatty acid oxidation, decreased fat mass and improved insulin sensitivity.[3]
### BAM15: a mitochondrial uncoupler
BAM15 dissipates the mitochondrial proton gradient, increasing respiration and energy expenditure.[4] In mice with diet-induced obesity, it increased nutrient oxidation and decreased body fat without changing food intake, lean mass or body temperature, and improved insulin sensitivity in clamp studies.[5] In vascular smooth muscle cells it potently activated AMPK.[6]
### What the combination evidence covers
BAM15 has been combined with another metabolic agent in one mouse study: with the thyroid hormone receptor-β agonist MGL-3196, it gave better energy expenditure, liver fat loss and glucose control than either monotherapy in a fatty liver disease model.[7] That result does not transfer to SLU-PP-332, and any interaction between an ERR agonist and an uncoupler remains unstudied.Because the label does not state the ratio of the two compounds, HPLC and mass-spectrometry certificates of analysis are the practical way to confirm composition.

## Research Status

Neither SLU-PP-332 nor BAM15 is FDA approved, and the combination has no clinical development program. The cited evidence for both is preclinical, from cell and rodent models.[8][4]The two differ in oral exposure data. SLU-PP-332's developers reported that it lacks oral bioavailability, which led to the orally bioavailable analog SLU-PP-915,[9] while BAM15 was reported to be orally bioavailable in mice.[5] Reviewers also note BAM15's high lipophilicity as a development challenge.[4] Exercise mimetics are prohibited in sport by the World Anti-Doping Agency, and human liver metabolites of SLU-PP-332 have been characterized for doping control.[10]Beyond obesity models, SLU-PP-332 improved ejection fraction, reduced fibrosis and increased survival in a mouse model of pressure-overload heart failure.[11] For the blend itself, there are no stability, pharmacokinetic or safety data. Supplier-made blends are sold for laboratory research use only.

## FAQ

**What is in the SLU-PP-332 + BAM15 blend?**
The blend contains SLU-PP-332, a synthetic agonist of the estrogen-related receptors ERRα, β and γ, and BAM15, a synthetic mitochondrial uncoupler. One supplier lists it as 300 mcg capsules without stating the split between the two. Neither is a peptide, and the blend is a supplier-defined research formulation, not an approved product.

**Has the SLU-PP-332 and BAM15 combination been studied?**
No published study has tested SLU-PP-332 together with BAM15. Each compound has been studied separately in cell and mouse models, where both increased energy expenditure and fat oxidation. BAM15 has been combined with a different compound, MGL-3196, in a mouse fatty liver model, but that result does not apply to this pairing.

**How is SLU-PP-332 different from BAM15?**
SLU-PP-332 activates estrogen-related receptors, nuclear receptors that switch on genes for mitochondrial biogenesis and fatty acid oxidation, and is studied as an exercise mimetic. BAM15 acts directly on mitochondria, dissipating the proton gradient so that respiration is less coupled to ATP production. Both raised energy expenditure in obese mice.

**Is the SLU-PP-332 + BAM15 blend FDA approved?**
No. Neither SLU-PP-332 nor BAM15 is FDA approved, and the combination has no clinical development program. The cited evidence for both compounds comes from cell and animal studies. Exercise mimetics are also prohibited in sport by WADA. Supplier-made blends are sold for laboratory research use only.

## References

1. Liu Z, Wang W, Wang S, et al. Mitochondrial uncoupler BAM15 ameliorates liver lipid metabolism disorders by activating the AMPK pathway. The FEBS journal 2026. PMID: 41527408
2. Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS chemical biology 2023. PMID: 36988910
3. Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. The Journal of pharmacology and experimental therapeutics 2024. PMID: 37739806
4. Xiong G, Zhang K, Ma Y, et al. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Frontiers in endocrinology 2023. PMID: 37900126
5. Alexopoulos SJ, Chen SY, Brandon AE, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature communications 2020. PMID: 32409697
6. Tai Y, Li L, Peng X, et al. Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Acta pharmaceutica Sinica. B 2018. PMID: 30505660
7. Zhou M, Li C, Byrne FL, et al. Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease. Acta physiologica (Oxford, England) 2024. PMID: 39152636
8. de Souza-Lima J, Astrosa-Martin BD, Galaz-Rodríguez CA, et al. [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. Revista medica de Chile 2026. PMID: 42024694
9. Billon C, Appourchaux K, Côté I, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. The Journal of pharmacology and experimental therapeutics 2026. PMID: 41421047
10. Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug testing and analysis 2026. PMID: 41688415
11. Xu W, Billon C, Li H, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation 2024. PMID: 37961903